MAGE-A4 Double Nickase Plasmid (h): sc-403486-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAGE-A4 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MAGE-A4 Double Nickase Plasmid (h) and MAGE-A4 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MAGEA4. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A4 Double Nickase Plasmid (h) | sc-403486-NIC | 20 µg | $410.00 | |||
MAGE-A4 Double Nickase Plasmid (h2) | sc-403486-NIC-2 | 20 µg | $410.00 |
MAGEA4 encodes MAGE-A4, a cancer-testis antigen normally enriched in germ cells but aberrantly expressed in multiple tumor contexts, making it a useful marker for studying lineage restriction and epigenetic reactivation. MAGE-A4 is implicated in protein–protein interaction networks that can influence ubiquitin-dependent proteostasis, transcriptional regulation, and cellular stress responses, including pathways linked to apoptosis and immune recognition. Its expression is frequently associated with altered chromatin states and DNA methylation dynamics, providing a model for investigating transcriptional derepression and antigen presentation biology. In biomedical research, MAGEA4 is commonly examined in relation to tumor cell fitness, immune-targetable antigen landscapes, and mechanisms controlling cancer-testis gene expression.
MAGE-A4 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MAGEA4 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MAGEA4. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MAGEA4 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MAGEA4-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.